 AK42 is a specific inhibitor of CLC2, which is a protein essential for maintaining proper levels of chloride in cells. This protein has been implicated in several diseases, such as leukodystrophy and primary aldosteronism. AK42 binds to certain residues on the protein, blocking it from functioning properly. By studying the structure of this protein, researchers have identified these residues and how they interact with AK42. These findings provide insight into the mechanism by which AK42 works to inhibit CLC2 and could lead to new treatments for diseases involving abnormal chloride levels. This article was authored by Daoma, Lei Wang, Anping Chai and others.